PT-141 vs oxytocin: evidence, cost, and legality

Which is better, PT-141 or oxytocin?

PT-141 wins for the sexual desire use case on both evidence and regulatory grounds: it is FDA approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder on the strength of the RECONNECT trials, even though an independent reanalysis argues the effect sizes (0.30 to 0.42 points on the desire domain) are below clinical meaningfulness. Oxytocin is FDA approved only as an obstetric injectable; its intranasal use rests on one negative crossover study for sexual function and on mixed meta-analyses in autism. Neither is approved for men, and PT-141's intranasal male program was abandoned over blood pressure effects. [1] [4] [5] [7] [8]

How do PT-141 and oxytocin compare?

PT-141 (bremelanotide) and Oxytocin compared by dimension
Dimension	PT-141 (bremelanotide)Favored	Oxytocin
Evidence for sexual function [1] [2] [3] [5]	Two identical 24 week randomized, double-blind, placebo-controlled phase 3 trials (n = 1,267 premenopausal women): FSFI desire domain rose 0.30 and 0.42 points versus placebo and distress fell 0.37 and 0.29 points. In men, small phase 1 and 2 intranasal studies showed erectile responses, including in sildenafil non-responders.	One double-blind, placebo-controlled crossover study of intranasal oxytocin 24 IU in 29 healthy couples: no change in sexual drive, arousal, erection, or lubrication; small to moderate increases in orgasm intensity and post-sex contentment, larger in men.
How meaningful the effect is [4] [5]	Statistically significant but questioned: a 2024 critical reanalysis argues the desire and distress changes fall below thresholds for clinical meaningfulness.	No effect on the primary sexual function measures; the secondary orgasm and contentment findings came from a single small study and have not been replicated.
FDA approved indication [7] [8]	Vyleesi, approved June 21, 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Not indicated for postmenopausal women or men.	Pitocin and generics, approved for labor induction and augmentation and for control of postpartum bleeding. No intranasal oxytocin product is FDA approved in the United States.
Mechanism [6] [7] [8]	Melanocortin receptor agonist (mainly MC4R, also MC3R) acting in hypothalamic circuits for sexual arousal and appetite; also stimulates MC1R on melanocytes, which explains focal skin darkening.	Binds the oxytocin receptor on uterine and mammary smooth muscle and on limbic and hypothalamic neurons involved in bonding and stress. Peripheral oxytocin crosses the blood brain barrier poorly, and how much intranasal oxytocin reaches central receptors in humans is debated.
Route and dosing from labels and trials [5] [7] [8]	1.75 mg subcutaneously by autoinjector at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours and no more than eight doses per month.	Obstetric use is intravenous infusion or intramuscular injection under the Pitocin label. Research nasal sprays used 24 IU as a single dose; there is no established intranasal dose for sexual function.
Side effects [1] [7] [8]	Nausea in about 40% (13% needed an antiemetic), flushing about 20%, injection site reactions about 13%, headache about 11%, a transient rise in blood pressure of about 6 mmHg systolic with a fall in heart rate after each dose, and focal hyperpigmentation in about 1%.	Injectable: uterine hyperstimulation, fetal distress, water intoxication with hyponatremia after prolonged high dose infusion, hypotension after rapid bolus. Intranasal: nasal irritation, headache, drowsiness; long term safety of repeated nasal dosing is not established.
Regulatory and compounding status [7] [8] [9]	Approved drug. Some 503A pharmacies compound bremelanotide vials and nasal sprays under the approved drug component pathway; those formulations are not FDA approved and the nasal route was abandoned by the sponsor.	Approved injectable. 503A pharmacies may compound oxytocin nasal sprays or lozenges under a prescription because it is a component of an approved drug; these products are not FDA approved and have not been shown to reach meaningful brain levels.
Typical cost [7] [8] [9]	Vyleesi list price roughly 900 USD per carton of four autoinjectors, with a manufacturer copay program near 99 USD per carton for commercially insured patients. Compounded PT-141 through telehealth typically 100 to 300 USD per vial or spray.	Generic oxytocin injection costs a few USD per vial. Compounded intranasal oxytocin through telehealth or peptide clinics typically 50 to 150 USD per month.
Note: Prices verified on the last verified date and change often.
WADA status [10]	Not on the WADA Prohibited List.	Not on the WADA Prohibited List.
Note: Neither is prohibited in sport.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

PT-141 (bremelanotide) and Oxytocin: grade, status, and cost
Attribute	PT-141 (bremelanotide)	Oxytocin
Class	Cyclic heptapeptide melanocortin receptor agonist (MC4R and MC3R), an active metabolite of Melanotan II	Endogenous nine amino acid neuropeptide hormone (cyclic nonapeptide) produced in the hypothalamus and released from the posterior pituitary
What it is	FDA approved (Vyleesi, 2019) for low sexual desire in premenopausal women; effect is small and nausea affects about 40% of users.	FDA approved injectable (Pitocin) for labor and postpartum bleeding; intranasal use for bonding, libido, or autism rests on small, mixed trials.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: FDA approved
Compounding	FDA approved as Vyleesi (bremelanotide injection) on June 21, 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Because bremelanotide is the active ingredient of an approved drug, some 503A pharmacies compound it under the approved drug component pathway, but compounded PT-141 vials and nasal sprays are not FDA approved formulations, have not been tested for potency or sterility by FDA, and the nasal route was abandoned by the sponsor over blood pressure effects. Use in men is off-label.	Oxytocin injection is FDA approved (Pitocin and generics) for obstetric indications. Because oxytocin is the active ingredient of an approved drug, 503A pharmacies may compound it in other dosage forms such as nasal sprays or lozenges for individual prescriptions; these compounded products are not FDA approved, have no approved indication, and have not been shown to achieve meaningful brain levels. Oxytocin is a 9 amino acid peptide and was not among the products transitioned to biologic status in March 2020, so it remains eligible for compounding. No intranasal oxytocin product is FDA approved in the United States.
WADA	WADA: Not WADA prohibited	WADA: Not WADA prohibited
Routes	Subcutaneous injection by autoinjector, on demand (Vyleesi), Intranasal (discontinued development program for men), Compounded subcutaneous vials and nasal sprays (not FDA approved formulations)	Intravenous infusion or intramuscular injection (Pitocin, approved), Intranasal spray (compounded or imported; not FDA approved in the United States), Sublingual and oral lozenges (compounded; no absorption data)
Typical cost	Vyleesi retail cash prices run about 930 to 956 USD per carton of four autoinjectors; the manufacturer savings program lists 0 USD for most commercially insured patients and 99 USD per carton without coverage. Compounded PT-141 nasal spray through a licensed telehealth program is about 187 to 224 USD per month. Prices checked 2026-09-22 and change often.	Generic oxytocin injection costs about 1.52 to 4.37 USD per vial in a published cash listing and is used in hospitals. Compounded oxytocin nasal spray through licensed telehealth programs runs about 115 to 135 USD per month. Prices checked 2026-09-22.
Last verified	Sep 22, 2026	Sep 23, 2026

Has PT-141 been tested directly against oxytocin?

No published trial has compared PT-141 and oxytocin directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do PT-141 and oxytocin cost?

Typical cost of PT-141 (bremelanotide) and Oxytocin
Dimension	PT-141 (bremelanotide)	Oxytocin
Typical cost	$187 to $224 per month	$115 to $135 per month
Price detail	PT-141 (bremelanotide) price by channel	Oxytocin price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Which works better for low libido, PT-141 or oxytocin?

PT-141 has the evidence. Two phase 3 trials in 1,267 premenopausal women showed small but statistically significant gains in desire and reductions in distress, and it is FDA approved for that use. Intranasal oxytocin showed no effect on sexual drive or arousal in its one placebo-controlled crossover study in couples. [1] [5] [7]

Is either one approved for men?

No. Vyleesi is indicated only for premenopausal women, and PT-141's intranasal program in men with erectile dysfunction was discontinued over blood pressure increases despite positive small studies. Oxytocin's approvals are obstetric. Any use in men is off-label. [2] [3] [7] [8]

How large is PT-141's effect?

Modest. The desire domain improved by 0.30 and 0.42 points versus placebo in the two trials, and a 2024 reanalysis argues those changes are below the threshold for clinical meaningfulness. About 40% of treated women had nausea. [1] [4] [7]

Does nasal oxytocin actually reach the brain?

Uncertain. Peripheral oxytocin crosses the blood brain barrier poorly, intranasal delivery is proposed to reach the brain through olfactory and trigeminal pathways, and how much reaches central receptors in humans is debated. Meta-analyses in autism show benefit on social functioning but not on non-social symptoms, and no nasal product is FDA approved. [6] [8] [9]

Which has the more serious safety concerns?

PT-141 raises blood pressure transiently after each dose and is contraindicated in uncontrolled hypertension or known cardiovascular disease; it also slows gastric emptying enough to reduce absorption of oral naltrexone. Injectable oxytocin's serious risks are obstetric. For compounded nasal oxytocin the main concern is the absence of long term safety data rather than a known harm. [7] [8]

Conditions studied

From the blog

Peptides for women, ranked by human evidence
GLP-1 drugs, teriparatide, abaloparatide, and Vyleesi (PT-141) have real trials in women. Kisspeptin is research-only and GHK-Cu rests on small skin studies. The ranking and legal status.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). PT-141 vs oxytocin: evidence, cost, and legality. https://peptideagent.ai/compare/pt-141-vs-oxytocin
HTML link: <a href="https://peptideagent.ai/compare/pt-141-vs-oxytocin">PT-141 vs oxytocin: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.